Skip to main content
Signal8

Vaxart, Inc. (VXRT)

Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vaxart, Inc. logo

Vaxart, Inc.

OTC:VXRTHealthcare
AH+0.00%$0.3550
Close$0.3550-1.86%
Mkt Cap$86.51M
EV-
Float240.64M
O/S243.7M
VOL401K sh
$ Vol$144K
RVOL1.27×
Inst Own0.0%
SI1.0%
Net Cash/Sh-
Dilution
Vaxart, Inc. logoOTC:VXRTAH$0.3550+0.00%
Short interest (FINRA)
1.0%
Oct 30 (18d)

Float 240.64M · Signal8 dilution snapshot · Nov 5, 2026

2.4M
Oct 30 (18d)prev 2.4M▲ 0.5%
3.95
Oct 30 (18d)prev 4.85▼ 18.6%
Borrow (IBKR)

The cost to borrow VXRT shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
11.5%
Nov 17 (0d)prev 39.1%▼ 27.6 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

436
Oct 22 (26d)prev 2.9K▼ 84.7%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver18 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20262.4M sh
Oct 15, 20262.4M sh
Sep 30, 20262.3M sh
Sep 15, 20262.3M sh
Aug 31, 20262.3M sh
Latest fails to deliver
DateShares failed
Oct 22, 2026436 sh
Oct 14, 20262.9K sh
Oct 13, 20261.6K sh
Sep 28, 2026625 sh
Sep 21, 2026400 sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 17
Latest sessions
DateReported short
Nov 17, 202611.5%
Nov 16, 202639.1%
Nov 13, 20266.5%
Nov 12, 202629.7%
Nov 11, 202628.6%
91-session median 29.5%mean 30.0%range 6.2–69.3%

130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for VXRT: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 2,417,496 VXRT shares were sold short (1.00% of a 240.64M-share float, 3.95 days to cover).